This is a working overview of obesity research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Interactions == Drug interactions with drotrecogin have not been systematically studied in patients with severe sepsis. Caution should be exercised when using other drugs that affect hemostasis concomitantly with drotrecogin (e.g. aspirin, warfarin, clopidogrel). However, the use of low dose prophylactic Heparin did not affect safety when given concurrently with drotrecogin.
=== 1849–1950: Early history === Pfizer was founded in 1849 as Charles Pfizer & Company by Charles Pfizer and Charles F. Erhart, two cousins who had immigrated to the United States from Ludwigsburg, Germany. The business produced chemical compounds, and was headquartered on Bartlett Street in Williamsburg, Brooklyn, where it produced an antiparasitic called santonin. This was an immediate success, although it was production of citric acid that led to Pfizer's growth in the 1880s. Pfizer continued to buy property in the area (by now the Williamsburg district of the city of Brooklyn, New York and beginning in 1898, the City of Greater New York) to expand its lab and factory, retaining offices on Flushing Avenue until the 1960s; the Brooklyn plant ultimately closed in 2009. Following its success with citric acid, Pfizer (at the now-demolished 295 Washington Avenue) and Erhart (at 280 Washington Avenue) established their main residences in the nearby Clinton Hill district, known for its concentration of Gilded Age wealth. In 1881, Pfizer moved its administrative headquarters to 81 Maiden Lane in Manhattan, presaging the company's expansion to Chicago, Illinois, a year later. By 1906 sales exceeded $3 million. World War I caused a shortage of calcium citrate. Pfizer imported the compound from Italy for the manufacture of citric acid, and due to the disruption in supply, the company began a search for an alternative. They found this in the form of a fungus capable of fermenting sugar to citric acid.
=== Canada, United States, Mexico === Ractopamine use as a feed additive is authorized in the United States, Canada, and Mexico. In the US, ractopamine is allowed to be used at a feed concentration of 5–20 mg/kg feed for finishing pigs and in dosages of 5–10 mg/kg feed for finishing pigs heavier than 109 kg. The maximum residue limit for ractopamine for meat in the US is 50 parts per billion (ppb), or five times the standard set by the Codex Alimentarius. Ractopamine was approved by the FDA in 1999 for use in swine, in 2003 for use in cattle, and in 2008 for use in turkeys. In 2015, the USDA approved of a new label, "No ractopamine — a beta-agonist growth promotant" to be used. The Canadian Food Inspection Agency (CFIA) maintains the Canadian Ractopamine-Free Pork Certification Program (CRFPCP) so that Canadian exports to Asian countries are not disallowed by their authorities. Hundreds of commercial feed facilities, including some from overseas, are enrolled in the CRFPCP, a programme that is essentially based on self-certification and backed up by a randomized testing policy. Currently, the label for USDA organic means no synthetic compounds can be used other than those on the list of allowed synthetics; therefore, ractopamine would not be allowed in certified organic production.
He also said that the government would also target 86 more people and companies connected to President Putin, including people who were "actively undermining the impact of existing sanctions". Sunak said that the new sanctions were made to ensure Russia paid "a price for its illegal activity" and urged other G7 countries to follow suit. The United States also announced that it would tighten export controls to Russia, particularly with regard to militarily important goods, and impose nearly 300 new sanctions against targets linked to Russia. Canada also imposed sanctions on targets linked to the Russian military, relatives of listed persons, members of the Kremlin elite, and those involved in human rights violations. In response to these sanctions, the Russian Foreign Ministry announced a ban on entry into the country on 500 Americans including former President Barack Obama, comedians Stephen Colbert, Jimmy Kimmel and Seth Meyers, Senators JD Vance, Katie Britt and Eric Schmitt, former US Ambassador Jon Huntsman Jr., presumptive Chairman of the Joint Chiefs of Staff General Charles Q. Brown Jr. and several journalists of CNN. Also included were officials involved in the prosecution of participants in the United States Capitol attack in 2021. It also continued to deny US consular access to detained journalist Evan Gershkovich in retaliation for the blocking of entry to Russian journalists during Foreign Minister Sergei Lavrov's visit to the UN in New York in April 2023.
=== Selected articles === Aramwit, P., & Sangcakul, A. (2007). The effects of sericin cream on wound healing in rats. Bioscience, biotechnology, and biochemistry, 71(10), 2473–2477. Aramwit, P., Kanokpanont, S., De-Eknamkul, W., & Srichana, T. (2009). Monitoring of inflammatory mediators induced by silk sericin. Journal of bioscience and bioengineering, 107(5), 556–561. Aramwit, P., Bang, N., & Srichana, T. (2010). The properties and stability of anthocyanins in mulberry fruits. Food research international, 43(4), 1093–1097. Aramwit, P., Kanokpanont, S., Nakpheng, T., & Srichana, T. (2010). The effect of sericin from various extraction methods on cell viability and collagen production. International Journal of Molecular Sciences, 11(5), 2200–2211. Aramwit, P., Siritientong, T., & Srichana, T. (2012). Potential applications of silk sericin, a natural protein from textile industry by-products. Waste Management & Research, 30(3), 217–224.
Sources: en.wikipedia.org
==== Chain length ==== A common means of expressing the length of a chain is the degree of polymerization, which quantifies the number of monomers incorporated into the chain. As with other molecules, a polymer's size may also be expressed in terms of molecular weight. Since synthetic polymerization techniques typically yield a statistical distribution of chain lengths, the molecular weight is expressed in terms of weighted averages. The number-average molecular weight (Mn) and weight-average molecular weight (Mw) are most commonly reported. The ratio of these two values (Mw / Mn) is the dispersity (Đ), which is commonly used to express the width of the molecular weight distribution. The physical properties of polymer strongly depend on the length (or equivalently, the molecular weight) of the polymer chain. One important example of the physical consequences of the molecular weight is the scaling of the viscosity (resistance to flow) in the melt. The influence of the weight-average molecular weight (
The Earth's cold trap is located about 12 km above sea level, well below the height at which water vapor would be permanently split apart into hydrogen and oxygen by solar UV rays, with the former irreversibly being lost to space. Because of the cold trap in the Earth's atmosphere, the Earth is losing water to space at a rate of only about 1 millimeter of ocean every 1 million years. At that rate, it would take trillions of years for all of its water to disappear, a timescale far longer than Earth's remaining life expectancy. A warmer atmosphere can hold more moisture, consistent with the Clausius–Clapeyron relation. Even with localized warming, the modern cold trap remains robust enough to prevent significant water vapor from being lost to space. However, the gradual luminosity increase of the Sun as it ages will weaken the cold trap over the next billion years by driving a warmer troposphere and stratosphere. This will elevate the mixing ratio of water vapor at the tropopause, allowing moisture to bypass the freeze-drying effect and ascend into the upper atmosphere where it will be dissociated by solar UV rays, leaving hydrogen to escape into space. As a result, the Earth is projected to ultimately lose its oceans to space in approximately 1 to 1.3 billion years, well before the Sun expands into a red giant.
Furthermore, harkening back to Urey's original hypothesis of a "post-impact" reducing atmosphere, a recent atmospheric modeling study has shown that an iron-rich impactor with a minimum mass around 4×1020 – 5×1021 kg would be enough to transiently reduce the entire prebiotic atmosphere, resulting in a Miller–Urey-esque H2-, CH4-, and NH3-dominated atmosphere that persists for millions of years. Previous work has estimated from the lunar cratering record and composition of Earth's mantle that between four and seven such impactors reached the Hadean Earth.
=== Use as a fat loss supplement === 3,5-Diiodo-L-thyronine and 3,3′-diiodo-L-thyronine are used as ingredients in certain over-the-counter fat-loss supplements, designed for bodybuilding. Several studies have shown that these compounds increase the metabolization of fatty acids and the burning of adipose fat tissue in rats.
Sources: en.wikipedia.org
For example, α-cobra toxin, erabutoxin A, and candoxin contain three adjacent loops coming up from a globular, small and hydrophobic core that is cross-linked by four conserved disulfide bridges. This conservation suggests the presence of essential functional elements that are shared among these neurotoxins. Lastly, the abundance of the disulfide bonds and the limited secondary structure that is observed in the α-bungarotoxin explains its exceptional stability, which makes it resistant to denaturation even under extreme conditions such as boiling and exposure to strong acids.
== Contemporary developments and strategy == Throughout the 2020s TCI pursued an acquisition and expansion phase, increasing capacity for CDMO services, establishing additional labs, and extending product portfolios into probiotics, collagen, functional drinks and clinical-grade ingredients. The company emphasizes integrated R&D, regulatory compliance for international markets, and sustainability in manufacturing operations.
=== Suicide === The gabapentin prescribing information contains a warning of an increased risk of suicidal thoughts and behaviors. The warning is based on a meta-analysis of all approved antiepileptic drugs in 2008, and not with gabapentin alone. According to an experimental meta-analysis of insurance claims databases, gabapentin use is associated with an approximately 40% increased risk of suicide, suicide attempt, and violent death as compared with a reference anticonvulsant drug topiramate. The risk is increased for people with bipolar disorder or epilepsy. Another study has shown an approximately doubled rate of suicide attempts and self-harm in people with bipolar disorder who are taking gabapentin versus those taking lithium. A large Swedish study suggests that gabapentinoids are associated with an increased risk of suicidal behavior, unintentional overdoses, head/body injuries, and road traffic incidents and offenses. On the other hand, a study published by the Harvard Data Science Review found that gabapentin was associated with a significantly reduced rate of suicide. In addition, a 2010 study published by the Pharmacoepidemiology and Drug Safety journal concluded that although there was no significant suicide rate decrease between the pre-prescription window and the post-prescription window for the non-psychiatric population, significant reductions in suicide rates were observed in psychiatric persons.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.